The Cyclin D-CDK4/6-RB Axis: How Cells Enter the Division Cycle

From Growth Signal to D-Type Cyclin

Mitogenic signalling through the RAS-MAPK and PI3K pathways increases transcription and stability of the D-type cyclins (cyclin D1, D2 and D3). D-type cyclins are short-lived, so their level closely tracks the strength of the growth signal, making them a rheostat for cell-cycle entry.

Cyclin D turnover is controlled in part by the CRL4-AMBRA1 ubiquitin ligase. Hotspot mutations that stabilise cyclin D, or loss of AMBRA1, raise cyclin D levels and can reduce sensitivity to CDK4/6 inhibitors.

CDK4 and CDK6 Activation

D-type cyclins bind and activate CDK4 and CDK6. The active complex begins phosphorylating the retinoblastoma protein, and also sequesters the CIP/KIP inhibitors p21 and p27, freeing cyclin E-CDK2 to complete RB phosphorylation.

CDK4 is amplified in some sarcomas (often alongside MDM2), and CDK6 is overexpressed in certain leukaemias and lymphomas. Either event increases kinase activity toward RB.

The INK4 and CIP/KIP Brakes

Two inhibitor families restrain the axis. The INK4 proteins (p16INK4a from CDKN2A, plus p15, p18, p19) bind CDK4/6 directly and block cyclin D association. The CIP/KIP proteins (p21, p27, p57) have more complex, concentration-dependent effects across CDK-cyclin complexes.

Homozygous deletion or promoter methylation of CDKN2A removes p16 and is one of the most common events in human cancer, functionally mimicking CDK4/6 hyperactivation.

RB Phosphorylation and E2F Release

In its active, hypophosphorylated state, RB binds E2F transcription factors and recruits chromatin-repressive complexes to silence S-phase genes. Progressive phosphorylation by CDK4/6 and then CDK2 inactivates RB, releasing E2F and driving expression of cyclin E, DNA-replication factors and nucleotide-synthesis enzymes.

Biallelic RB1 loss makes the cell largely independent of upstream CDK4/6 activity. Tumours without functional RB are generally not expected to respond to CDK4/6 inhibitors, which is why RB status is central to interpreting this pathway.

How the Axis Is Read in a Report

A report may show CCND1 or CDK4/CDK6 amplification, CDKN2A loss, or RB1 alteration. These are not interchangeable: they sit at different points in the pathway and have different implications for drugs that act on it.

Copy-number calls also depend on tumour purity and assay design, and RB protein loss detected by immunohistochemistry is not identical to an RB1 sequence variant. The exact finding and method should travel with the result.

Key Takeaways

• ·Growth signals raise D-type cyclins, activating CDK4/6 to inactivate RB and release E2F.
• ·CDKN2A loss, CDK4/6 or cyclin D amplification, and RB1 loss all disrupt the axis by different mechanisms.
• ·CDK4/6 inhibitor activity generally depends on intact RB.
• ·Method and tumour context are part of any cyclin, CDK or RB result.